The chance to focus on an area of massive unmet medical need was a major factor in attracting Gabriel Baertschi to leave his previous role as president and general manager of AstraZeneca (LSE: AZN) in Japan to take the top job at Germany’s Grünenthal Group.
Mr Baertschi is also excited to have the chance to grow the independent, family-owned company’s revenues and reputation, he tells The Pharma Letter.
"The vision is to be a 2 billion euros company by 2022"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze